Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
2,225 stopped studies mapped to Malignant Digestive System Neoplasm and descendants · 91% state a reason
Over the 2,225 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT03695250 | BMS-986205 and Nivolumab as First or Second Line Therapy in Treating Patients With Liver… | Phase 1 / Phase 2 | terminated | Oct 4, 2018 | Edward Kim | Funding source decision to terminate study. | Funding |
| NCT05322577 | A Study Evaluating Bemarituzumab in Combination With Other Anti-cancer Therapies in…(FORTITUDE-103) | Phase 1 / Phase 2 | terminated | Apr 12, 2022 | Amgen | Sponsor Decision | Sponsor / business decision |
| NCT03835273 | Oesophagectomy and Chest Wall and Respiratory Function | — | terminated | Feb 8, 2019 | Imperial College London | Study closed before the planned recruitment target was reached because the study period ended… | Enrollment / accrual |
| NCT03941366 | Treatment of Adenocarcinoma of the Rectum With Transanal Local Excision for Complete… | N/A | terminated | May 7, 2019 | Henry Ford Health System | Lack of financial support | Funding |
| NCT05526079 | Watchful Waiting for Complete Responders to Therapy in Rectal Cancer | N/A | terminated | Sep 2, 2022 | Henry Ford Health System | Lack of financial support | Funding |
| NCT05714553 | NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours | Phase 1 / Phase 2 | terminated | Feb 6, 2023 | NuCana plc | The NuTide:303 study was terminated at NuCana's discretion following refinement of the NUC-3373… | Sponsor / business decision |
| NCT05377827 | Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of… | Phase 1 | suspended | May 17, 2022 | Washington University School of Medicine | Drugs/Equipment Unavailable | Other (stated, no rule matched) |
| NCT07152821 | Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory,…(BATTMAN) | Phase 3 | terminated | Sep 3, 2025 | Canadian Cancer Trials Group | Pharmaceutical Sponsor discontinued trial financial support | Funding |
| NCT06528093 | A Study to Find a Suitable Dose of BI 765883 and to Test Whether it Helps People With… | Phase 1 | terminated | Jul 30, 2024 | Boehringer Ingelheim | not stated | Not stated |
| NCT04469504 | Preoperative Prehabilitation for Sarcopenic Patients Prior to Pancreatic Surgery for…(PSOAS) | N/A | terminated | Jul 14, 2020 | University Hospital, Lille | The study was terminated prematurely due to patient inclusion difficulties. | Other (stated, no rule matched) |
| NCT05400122 | Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming… | Phase 1 | suspended | Jun 1, 2022 | David Wald | Drugs unavailable | Other (stated, no rule matched) |
| NCT02200042 | Radiation Therapy vs. Observation Following Gemcitabine and Cisplatin for Inoperable… | Phase 3 | terminated | Jul 25, 2014 | NRG Oncology | not stated | Not stated |
| NCT05451849 | A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer | Phase 1 / Phase 2 | terminated | Jul 11, 2022 | TCR2 Therapeutics | No participants were enrolled in Phase 2 as Phase I was terminated early due to the lack of a clear… | Enrollment / accrual |
| NCT04348643 | Safety and Efficacy of CEA-Targeted CAR-T Therapy for Relapsed/Refractory CEA+ Cancer | Phase 1 / Phase 2 | withdrawn | Apr 16, 2020 | Chongqing Precision Biotech Co., Ltd | The sponsor requested to terminate the study. | Other (stated, no rule matched) |
| NCT03114319 | Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors | Phase 1 | terminated | Apr 14, 2017 | Novartis Pharmaceuticals | Business reasons and not due to any safety concerns | Safety / toxicity |
| NCT05705791 | Clinical Investigation Evaluating Safety and Efficacy of Selective Intra-arterial…(HOLMBRAVE) | N/A | terminated | Jan 31, 2023 | Gustave Roussy, Cancer Campus, Grand Paris | Toxicities | Safety / toxicity |
| NCT06585488 | A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in… | Phase 1 | terminated | Sep 5, 2024 | BeOne Medicines | The Sponsor has made the decision to terminate this study due to the lack of promising efficacy,… | Efficacy / futility |
| NCT00640978 | Erlotinib and RAD001 (Everolimus) in Patients With Previously Treated Advanced Pancreatic… | Phase 2 | terminated | Mar 21, 2008 | M.D. Anderson Cancer Center | Significant Adverse Effects - Futility | Safety / toxicity |
| NCT06466187 | A Study of SGN-MesoC2 in Advanced Solid Tumors | Phase 1 | terminated | Jun 20, 2024 | Seagen, a wholly owned subsidiary of Pfizer | The trial was terminated for strategic reasons. The decision was not based on any safety concerns | Safety / toxicity |
| NCT05731947 | Evaluation of Revumenib in Participants With Colorectal Cancer and Other Solid Tumors | Phase 1 / Phase 2 | terminated | Feb 16, 2023 | Syndax Pharmaceuticals | Study was terminated by sponsor after Phase 1b as pre-defined signals of efficacy were not met in… | Efficacy / futility |
| NCT04809766 | Mesothelin-Specific T-Cells (FH-TCR-Tᴍsʟɴ) for the Treatment of Metastatic Pancreatic… | Phase 1 | terminated | Mar 22, 2021 | Fred Hutchinson Cancer Center | Study terminated due to end of funding. | Funding |
| NCT07369791 | Nivolumab Plus Relatlimab and Gemcitabine/Cisplatin as First-Line Treatment in Advanced…(NOBLE) | Phase 2 | withdrawn | Jan 27, 2026 | National Health Research Institutes, Taiwan | The study was terminated due to administrative reasons following the cancellation of collaboration… | Other (stated, no rule matched) |
| NCT01871571 | Bevacizumab, Fluorouracil, Leucovorin Calcium, and Oxaliplatin Before Surgery in Treating… | Phase 2 | terminated | Jun 6, 2013 | University of Southern California | Insufficient Accrual | Enrollment / accrual |
| NCT05967533 | The Immune Effects of Fermented Wheat Germ Nutritional Supplementation in Patients With… | Phase 1 | suspended | Aug 1, 2023 | University of California, Davis | For internal interim analysis | Efficacy / futility |
| NCT06779669 | Use of Alternative and Complementary Medicine by Colorectal Cancer Patients(ALTERNATIVCCR) | N/A | terminated | Jan 16, 2025 | University Hospital, Limoges | Not enough awnser in the qualitative study | Other (stated, no rule matched) |
| NCT04251715 | mFOLFIRINOX Followed by Hepatic Arterial Infusion of Floxuridine and Dexamethasone With… | Phase 2 | terminated | Feb 5, 2020 | OHSU Knight Cancer Institute | change in standard-of-care systemic therapy | Other (stated, no rule matched) |
| NCT03630640 | Neoadjuvant and Adjuvant Nivolumab in HCC Patients Treated by Electroporation(NIVOLEP) | Phase 2 | terminated | Aug 15, 2018 | Assistance Publique - Hôpitaux de Paris | Because patient recruitment was affected by the COVID-19 pandemic, the study sponsor and funding… | COVID-19 / pandemic |
| NCT06692959 | A Phase II Trial of Neoadjuvant PD-1 Vaccine PD1-Vaxx in Operable MSI High Colorectal…(Neo-POLEM) | Phase 2 | terminated | Nov 18, 2024 | University of Southampton | funding withdrawal | Funding |
| NCT04975516 | Standard of Care Chemotherapy With or Without Stereotactic Body Radiation Therapy for… | Phase 2 | terminated | Jul 23, 2021 | Mayo Clinic | Low/slow accrual | Enrollment / accrual |
| NCT05514717 | A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2 | Phase 1 | terminated | Aug 24, 2022 | Day One Biopharmaceuticals, Inc. | Development discontinued. | Other (stated, no rule matched) |
| NCT05537402 | LOcoregional vs Systemic Therapy in Patients With BCLC Stage B HCC(LOST-B) | Phase 2 | terminated | Sep 13, 2022 | University of Texas Southwestern Medical Center | The decision was made to close the study to enrollment due to poor overall accrual and the… | Enrollment / accrual |
| NCT02626312 | Radiation Therapy in Treating Patients With Hepatocellular Carcinoma, Cholangiocarcinoma,… | Phase 1 | terminated | Dec 10, 2015 | M.D. Anderson Cancer Center | \< 75% participation | Other (stated, no rule matched) |
| NCT04158635 | Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic… | Phase 1 | suspended | Nov 12, 2019 | City of Hope Medical Center | Accrual Goal met | Enrollment / accrual |
| NCT06902246 | Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma | Phase 2 | withdrawn | Mar 30, 2025 | University of Miami | Investigator decision | Investigator |
| NCT01148056 | Intensity Modulated Radiation Therapy (IMRT) for Patients With Rectal Cancer | N/A | terminated | Jun 22, 2010 | Massachusetts General Hospital | The study was closed to enrollment due to slow accrual. | Enrollment / accrual |
| NCT05576896 | Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in the… | Phase 2 | terminated | Oct 13, 2022 | Northwestern University | The study was closed due to accrual. | Enrollment / accrual |
| NCT07292285 | The Surveillance Nonoperative Watch & Wait (SNOWW) Rectal Cancer Trial.(SNOWW) | — | withdrawn | Dec 18, 2025 | University of Colorado, Denver | Sponsor decided not to move forward with the site. | Sponsor / business decision |
| NCT03676478 | Assessing Timing of Enteral Feeding Support in Esophageal Cancer Patients on Muscle…(EFECTS) | N/A | terminated | Sep 18, 2018 | University Hospital, Gasthuisberg | halted prematurely on the occasion of a planned sample size reestimation after 200 randomised… | Efficacy / futility |
| NCT05331040 | Radiomics in Rectal Cancer | — | withdrawn | Apr 15, 2022 | NHS Grampian | Ill health of CI | Other (stated, no rule matched) |
| NCT05419479 | Switch Maintenance in Pancreatic | Phase 1 / Phase 2 | suspended | Jun 15, 2022 | James Cleary, MD, PhD | Efficacy concerns. | Efficacy / futility |
| NCT05275075 | Identify microRNAs in Cachexia in Pancreatic Carcinoma(SCC-miRPanCa) | — | terminated | Mar 11, 2022 | University of Oklahoma | Translational scientist left university | Other (stated, no rule matched) |
| NCT06405061 | Evaluation of Effectiveness and Safety of HAIC in Combination With Adebrelimab and… | Phase 2 | suspended | May 8, 2024 | Tianjin Medical University Cancer Institute and Hospital | Mid-term data analysis for the project has been completed; enrollment is now suspended. | Enrollment / accrual |
| NCT07413510 | Precision Nursing vs Conventional Care in Laparoscopic Colorectal Cancer Surgery: A… | N/A | withdrawn | Feb 17, 2026 | Jiangsu Cancer Institute & Hospital | The trial was withdrawn before participant enrollment; no subjects were recruited and no data were… | Enrollment / accrual |
| NCT07152210 | Clinical Study on the Safety and Preliminary Efficacy of CDH17/GUCY2C CAR-T in the… | N/A | withdrawn | Sep 3, 2025 | Guangzhou Bio-gene Technology Co., Ltd | Due to corporate strategic adjustment. | Sponsor / business decision |
| NCT04975217 | Fecal Microbial Transplants for the Treatment of Pancreatic Cancer | Early Phase 1 | suspended | Jul 23, 2021 | M.D. Anderson Cancer Center | PI request | Other (stated, no rule matched) |
| NCT04588246 | Comparing Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to… | Phase 3 | terminated | Oct 19, 2020 | NRG Oncology | Inadequate accrual rate | Enrollment / accrual |
| NCT03745326 | Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor… | Phase 1 / Phase 2 | terminated | Nov 19, 2018 | National Cancer Institute (NCI) | Study was closed due to lack of accrual and study outcomes overlapped with another protocol's… | Enrollment / accrual |
| NCT05911243 | Feasibility of Auricular Acupressure for Appetite and Weight in Patients With Stage II-IV… | N/A | terminated | Jun 20, 2023 | University of Washington | Study closed per SRC Low Accrual Policy. | Enrollment / accrual |
| NCT01552434 | Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in… | Phase 1 | terminated | Mar 13, 2012 | M.D. Anderson Cancer Center | \< 75 % participation | Other (stated, no rule matched) |
| NCT03825289 | Trametinib and Hydroxychloroquine in Treating Patients With Pancreatic Cancer(THREAD) | Phase 1 | terminated | Jan 31, 2019 | University of Utah | Lack of Funding | Funding |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated Jul 29, 2026source: clinicaltrials